Tunlametinib (HL-085) Plus Vemurafenib in Patients with Advanced BRAF V600-mutant Solid Tumors: an Open-Label, Single-Arm, Multicenter, Phase I Study
Experimental Hematology and Oncology（2024）
Key words
Tunlametinib,MEK inhibitor,Vemurafenib,BRAF,Non-small cell lung cancer,Colorectal cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined